Glenmark Confirms Settlement of Litigation with Nycomed

Date: 06 May 2011

Press Release

Glenmark Generics Limited (“Glenmark”) has entered into a settlement and license agreement with Nycomed US to resolve the patent infringement lawsuit regarding Glenmark’s Abbreviated New Drug Application ("ANDA") for Fluticasone Propionate 0.05% Lotion, currently marketed by Nycomed US as CUTIVATE®.

Under the terms of the Settlement Agreement, Glenmark will be able to market and distribute its Fluticasone propionate lotion under a royalty-bearing license from Nycomed US in March 2012, or earlier in certain circumstances. Glenmark believes that it is entitled to 180 days of exclusivity with respect to its fluticasone propionate lotion, as the first generic company to file an ANDA for the product. CUTIVATE (Fluticasone Propionate) 0.05% Lotion had annual sales of approximately USD 48 million in the United States, based on IMS Health sales data ending December  2010.

About Glenmark Generics Limited.

Glenmark Generics Limited (GGL) is a subsidiary of Glenmark Pharmaceuticals Limited (Glenmark) and aims to be a global integrated Generic and API leader. GGL has an established presence in North America, a developing EU presence and Argentina and maintains marketing front-ends in these countries. It primarily sells its FDF products in the United States ("US") and the European Union ("EU"), as well as its oncology FDF products in South America. The Company supplies APIs to customers in approximately 63 countries, including the US, various countries in the EU, South America and India.

#####

Download PDF